SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

DEFA14A - OmniAb, Inc. (0001846253) (Filer)

DEF 14A - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. "Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team's execution, and puts us on pace for one of our strongest years ever in partner adds. Additionally, a recent further streamlining of our operations enhances the scalability and long-term value of our business," said Matt Foehr, Chief E

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:  OmniAb conference call to discuss second quarter 2025 financial results and business updates     Date:  Wednesday, August 6, 2025     Time:  4:30 p.m. Eastern time (1:30 p.m. Pacific time)     Phone: U.S. (800) 549 8228   International (289) 819 1520   Conference ID is 93102     Webcast: Live a

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB:AVAI), Tempus Ai, Inc. (NASDAQ:TEM), OmniAb, Inc. (NASDAQ:OABI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Recursion Pharmaceutic

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb's Partners for Use in Their Own Laboratories OmniAb, Inc. (NASDAQ:OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb's proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508776052/en/ "xPloration has been a core

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")) for the development of a novel bispecific antibody drug conjugate ("bsADC") program targeting solid tumors. The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC") linker technology and conjugation expertise to support next-generation therapeutic discovery. "This partnership brings together two highly co

OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1st Annual Royalty Company Virtual Conference, May 13. Management will participate in a fireside chat and a panel discussion on Tuesday, May 13th. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors on Tuesday, May 20th. RBC Capital Markets Global Healthcare Conference, May 20-21 at the InterContinental Barclay Hotel in New York City. Management will hold one-on-one meetings with investors on Wednesday, May 21st. Benchmark 2025 Health

Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology OmniAb, Inc. (NASDAQ:OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directors to seven. "We're delighted to welcome Phil and Steve to our Board of Directors. Their extensive

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2025 financial results and business updates       Date:   Thursday, May 8, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 96760    

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

Cowen initiated coverage of OmniAb with a rating of Outperform and set a new price target of $10.00

H.C. Wainwright initiated coverage of OmniAb with a rating of Buy and set a new price target of $11.00

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13D/A - OmniAb, Inc. (0001846253) (Subject)